Andrew Forman's practice involves counseling clients in a wide range of antitrust matters, with a specific focus on mergers and acquisitions, joint ventures, and representing clients in connection with investigations by the U.S. Department of Justice and the Federal Trade Commission (FTC). Andy also has experience in private antitrust litigation, including antitrust class action litigation. He has represented clients in matters involving a variety of industries, including the pharmaceutical, medical device, airline, automobile, software, semiconductor, industrial and engineered products, and consumer products industries. Among the clients Andy has represented are Eli Lilly, Salix, Anheuser-Busch InBev, US Airways, Pfizer, Microsoft, and Goodyear.
Recognized as a leading antitrust lawyer, Andy was recommended in The Legal 500 (2012 -2013) for his work in merger clearances and was part of the team accepting Benchmark Litigation's award for 2013 U.S. Antitrust Group of the Year and for a national Impact Case of the Year awardfor the US Airways/American merger clearance. His work for US Airways in connection with its merger with American Airlines was also recognized by Global Competition Review as the 2014 Matter of the Year. More recently, Andy's antitrust clearance work in connection with Eli Lilly & Company's acquisition of Novartis Animal Health was nominated for the Global Competition Review's 2015 Matter of the Year.
Prior to joining Cadwalader, Andy worked for the FTC's Bureau of Competition (Mergers I), where he helped lead antitrust investigations in large mergers and acquisitions in the pharmaceutical, medical device, consumer products, industrial products, and aircraft components industries.
Andy received his J.D., cum laude, from Georgetown University and his undergraduate degree as an Honors Graduate from Washington University in St. Louis. Following law school, he served as a judicial law clerk for the D.C. Court of Appeals. He is admitted to the bar in the District of Columbia and Maryland.
•Senior Judges' Chambers
District of Columbia Court of Appeals
Antitrust representations include:
•Salix Pharmaceuticals, Ltd. in connection with its approximately $14.5 billion total enterprise value acquisition by Valeant Pharmaceuticals International, Inc.
•Eli Lilly & Company in connection with its $5.4 billion acquisition of Novartis Animal Health.
•Acorda Therapeutics, Inc. in its pending acquisition of Civitas Therapeutics, Inc.
•Salix Pharmaceuticals in connection with its proposed transaction with Cosmo Technologies.
•US Airways in its $17 billion merger with American Airlines.
•Vertis Holdings, Inc., an advertising and direct mail company, in connection with its bankruptcy sale to rival Quad/Graphics, Inc.
•US Airways in its slot transaction with Delta Air Lines.
•Pfizer Inc. in its $68 billion acquisition of Wyeth Pharmaceuticals.
•Microsoft Corporation in numerous antitrust matters.
•Elan Corporation PLC in the $3.3 billion sale of its multiple sclerosis joint venture interest to Biogen Idec, Inc.
•Anheuser-Busch InBev in various antitrust matters.
•Goodyear Tire & Rubber Company in various antitrust matters.
News & Resources
•Cadwalader Represents Salix Pharmaceuticals in Its Pending Acquisition by Valeant Pharmaceuticals Feb 22, 2015
•New Deals - Lawyers on Major Transactions Jan 29, 2009
•Cadwalader's Antitrust Group Nominated for Pair of 2015 Global Competition Review Awards Feb 20, 2015
Clients & Friends Memos
•Takeaways from the Ninth Circuit's Opinion Affirming the FTC's Victory Against the St. Luke's/Saltzer Merger Feb 12, 2015
•So The Agency Wants to Talk: Advice and Issues in Pre-Complaint Depositions Mar 16, 2015